Loading
Immunotherapy patents start expiring around 2028. Guaranteeing in advance to buy cheap copies for poorer countries would make sure manufacturers build the capacity.
Pembrolizumab and nivolumab lose their core patent protection in the largest markets from about 2028; biosimilar developers are targeting high-income markets first, and LMIC supply may lag by years as it did for trastuzumab. Gavi's pneumococcal advance market commitment showed that a guaranteed purchase at a ceiling price can accelerate manufacturing investment for poorer markets. The proposal is a donor- and government-backed commitment to buy a defined volume of WHO-prequalified PD-1 biosimilars for LMIC programmes at a ceiling price (for example under $500 per dose) from 2028, with WHO prequalification and pooled procurement handling quality and distribution.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care, Nivolumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Nivolumab, Pembrolizumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Nivolumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value, Pembrolizumab.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation, Prices and value.